An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies - VanBlargan, Laura A.; Errico, John M.; Halfmann, Peter J.; Zost, Seth J.; Crowe, James E.; Purcell, Lisa A.; Kawaoka, Yoshihiro; Corti, Davide; Fremont, Daved H.; Diamond, Michael S. (Nature medicine, 2022)
Keywords: 631/326/596/2558; 631/326/596/4130; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - therapeutic use; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cancer Research; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Humans; Immunoglobulin G; Infectious Diseases; Metabolic Diseases; Molecular Medicine; Monoclonal antibodies; Mutation; Neurosciences; Neutralization; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike protein; Viral diseases; Viruses